Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PVC · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| PVC (daily for 21 days, 7 days off) | DRUG | - |
| PVC (twice weekly) | DRUG | - |
Inclusion Criteria: Generally healthy postmenopausal women with symptoms of atrophic vaginitis including vaginal dryness, vaginal itching, vaginal burning, and/or painful intercourse. The subject must have a clinical diagnosis of atrophic vaginitis and an intact uterus. Exclusion Criteria: Women...
PVC is an investigational small molecule being developed for the treatment of atrophic vaginitis, a condition characterized by thinning and inflammation of the vaginal walls due to decreased estrogen levels. It is being studied in postmenopausal women aged 45 years and older.
PVC is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug.
PVC is currently in Phase 3 clinical development. It has completed one Phase 3 trial, which involved 480 participants. As an investigational drug, it has not yet been approved by regulatory authorities and remains under evaluation for its intended use.
PVC has been studied in one completed Phase 3 clinical trial with the identifier NCT00137371. This trial evaluated conjugated estrogen cream for atrophic vaginitis and enrolled 480 female participants in the United States and Canada. The study was randomized and double-blind.
PVC is the drug being evaluated in a clinical trial titled 'Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis.' The trial uses a conjugated estrogen cream formulation, which is the active treatment being tested for its effects on atrophic vaginitis symptoms.